Company Description
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products.
The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution.
In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses.
Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody.
The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2013 |
| IPO Date | Oct 31, 2018 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 919 |
| CEO | Emily Leproust |
Contact Details
Address: 681 Gateway Boulevard South San Francisco, California 94080 United States | |
| Phone | 800 719 0671 |
| Website | twistbioscience.com |
Stock Details
| Ticker Symbol | TWST |
| Exchange | NASDAQ |
| Fiscal Year | October - September |
| Reporting Currency | USD |
| CIK Code | 0001581280 |
| CUSIP Number | 90184D100 |
| ISIN Number | US90184D1000 |
| Employer ID | 46-2058888 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Emily Marine Leproust Ph.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Patrick John Finn Ph.D. | President and Chief Operating Officer |
| Paula Green | Senior Vice President of Human Resources |
| Dr. William Charles Banyai Ph.D. | Senior Vice President of Advanced Development, GM of Data Storage and Director |
| Adam Laponis | Chief Financial Officer |
| Robert F. Werner | Vice President and Chief Accounting Officer |
| Siyuan Chen | Chief Technology Officer |
| Dr. Aaron K. Sato Ph.D. | Chief Scientific Officer |
| Dr. Michael Fero Ph.D. | Chief Information Officer |
| Angela Bitting | Chief ESG Officer and Senior Vice President of Corporate Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 18, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 18, 2024 | 10-K | Annual Report |
| Nov 18, 2024 | 8-K | Current Report |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 12, 2024 | 144 | Filing |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |